These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22350071)

  • 1. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model.
    Pardo A; Stöcker M; Kampmeier F; Melmer G; Fischer R; Thepen T; Barth S
    Cancer Immunol Immunother; 2012 Oct; 61(10):1617-26. PubMed ID: 22350071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
    Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta.
    Nagai T; Tanaka M; Tsuneyoshi Y; Xu B; Michie SA; Hasui K; Hirano H; Arita K; Matsuyama T
    Cancer Immunol Immunother; 2009 Oct; 58(10):1577-86. PubMed ID: 19238383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.
    Kellner C; Bleeker WK; Lammerts van Bueren JJ; Staudinger M; Klausz K; Derer S; Glorius P; Muskulus A; de Goeij BE; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Aug; 371(1-2):122-33. PubMed ID: 21756911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.
    Simon N; Antignani A; Sarnovsky R; Hewitt SM; FitzGerald D
    J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
    Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity.
    Guo R; Cao L; Guo W; Liu H; Xu H; Fang Q; Hong Z
    Biochem Biophys Res Commun; 2016 Jun; 475(1):93-9. PubMed ID: 27178207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An epidermal growth factor receptor-targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer.
    Huang M; Park J; Seo J; Ko S; Yang YH; Lee Y; Kim HJ; Lee BS; Lee YS; Ko BJ; Jung ST; Park D; Yoo TH; Kim CH
    FASEB J; 2024 Jul; 38(13):e23759. PubMed ID: 38949635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
    Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
    Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
    Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
    Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
    Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
    Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
    Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
    Wolf P; Alt K; Bühler P; Katzenwadel A; Wetterauer U; Tacke M; Elsässer-Beile U
    Prostate; 2008 Feb; 68(2):129-38. PubMed ID: 18044731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
    Schmidt M; McWatters A; White RA; Groner B; Wels W; Fan Z; Bast RC
    Gynecol Oncol; 2001 Feb; 80(2):145-55. PubMed ID: 11161852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer.
    Fischer A; Wolf I; Fuchs H; Masilamani AP; Wolf P
    Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33260619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
    Schmidt M; Wels W
    Br J Cancer; 1996 Sep; 74(6):853-62. PubMed ID: 8826849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Turn a diarrhoea toxin into a receptor-mediated therapy for a plethora of CLDN-4-overexpressing cancers.
    Yao Q; Cao S; Li C; Mengesha A; Low P; Kong B; Dai S; Wei M
    Biochem Biophys Res Commun; 2010 Jul; 398(3):413-9. PubMed ID: 20599713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway.
    Yang Y; Tian Z; Ding Y; Li X; Zhang Z; Yang L; Zhao F; Ren F; Guo R
    J Immunol Res; 2018; 2018():1090287. PubMed ID: 30596104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.
    Stish BJ; Oh S; Chen H; Dudek AZ; Kratzke RA; Vallera DA
    Br J Cancer; 2009 Oct; 101(7):1114-23. PubMed ID: 19755995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotechnological and gene therapeutic strategies in cancer treatment.
    Wels W; Moritz D; Schmidt M; Jeschke M; Hynes NE; Groner B
    Gene; 1995 Jun; 159(1):73-80. PubMed ID: 7607575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.